drugset

drugset / Trial / NCT01320501

Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer

NCT01320501 ↗

Phase 4 Suspended 100 enrolled National Guard Health Affairs

NaSingle-groupOpen-labelTreatment

Summary

An open-label, prospective, single-arm, multi-center phase IV clinical trial of TarcevaTM as single agent

Timeline

Start: 2009-10
Primary completion: 2016-08
Completion: 2016-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erlotinib	Small molecule	150 mg	Oral

Indications